Expertise in
8
conditions

Mark N. Gaze

London, ENG, GB 
Expertise in
8
conditions
London, ENG, GB 

Overview

Mark Gaze practices practicing medicine in London, United Kingdom.

Mr. Gaze is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Rhabdomyosarcoma, Thyroidectomy, and Orchiectomy.

He is actively involved in clinical research, co-authoring 115 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 2/Phase 3
A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory Neuroblastoma
A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ch14.18/CHO
Study Phase: Phase 1
A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma
A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma
Enrollment Status: Completed
Publish Date: June 21, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

115 Total Publications

Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European paediatric Soft-tissue sarcoma Study Group (EpSSG).
Surgical nodal staging in rhabdomyosarcoma of the bladder and/or prostate with or without nodal or metastatic spread. A report from the European paediatric Soft-tissue sarcoma Study Group (EpSSG).
Journal: Journal of pediatric surgery
Published: April 16, 2026

Frequently Asked Questions about Mark N. Gaze

Is Mark N. Gaze a top-rated expert for Embryonal Tumor with Multilayered Rosettes?

MediFind is an objective health platform that identifies experts based on real-world data. Mark N. Gaze is classified as an Elite expert for Embryonal Tumor with Multilayered Rosettes, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mark N. Gaze participate in research or clinical trials?

Yes. Mark N. Gaze has published 115 articles and abstracts on conditions like Embryonal Tumor with Multilayered Rosettes. You can view a list of Mark N. Gaze's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gaze's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile